Don't Underestimate J&J's Best-Known Products

In the second of a three-part series I take a closer look at J&J's (NYSE: JNJ) consumer segment to find out if it could make the stock take off.

Mar 28, 2014 at 10:30PM

Despite being one of the major pharma stocks in the world, J&J (NYSE:JNJ) is a very diversified company. For instance, the consumer segment accounts for a significant proportion of revenue and, as such, is a key component of future returns for the stock. Therefore, it seems logical to take a deep dive into the consumer segment to see how it fits into J&J's overall operations.

Sales growth
Consumer products accounted for just over 20% of J&J's total sales in 2013. Overall, the segment delivered mild growth during the year, with sales for the consumer segment being 1.7% higher in 2013 than they were in 2012. This marks a turnaround from 2012, when sales for the segment fell by 2.9% year-over-year. In 2013, three of the six franchises delivered year-on-year growth, compared to just one in 2012.

However, when the effect of currency headwinds is taken into account, the results look much better. That's because negative currency effects reduced sales growth by 1.1%, meaning the operational growth figure was 2.8%. Sales outside of the U.S. were relatively strong, with operational sales growth (i.e., excluding negative currency impacts) of 3.1%, while in the U.S. operational sales growth of 2.3% was reported.

Franchises and margins
In terms of franchise sales growth within the consumer segment, the over-the-counter franchise was the top performer and delivered sales growth of 7%, growth driven by analgesics and upper-respiratory products. Indeed, all franchises with the exception of oral care performed significantly better year on year from 2012 to 2013 than from 2011 to 2012, although oral care's growth was only marginally down and was affected by the divestiture of the manual toothbrush product line in the U.S.

Meanwhile, pre-tax margins showed improvement in 2013 and went some way to returning to their 2011 levels after falling in 2012. A key reason for the improvement was cost-containment initiatives, which the company is targeting more of in the future, as well as gains on the sale of intangible assets. As 2012 margin was impacted by write-downs, margin improvements in 2013 may not be as strong at first glance but still show that J&J is making progress in reducing its operating expenses.

The competition
With regard to competition, sector peer Merck (NYSE:MRK) also has a consumer segment, although it is much smaller than that of J&J and accounted for 4.3% of Merck's total sales in 2013. Unlike J&J, Merck reported a decline in sales for its consumer segment in 2013, with the top line falling by 3% compared to 2012 figures (including a negative currency impact of 1%). The main reason for this was the termination in China of certain consumer care distribution arrangements, as well as a reversal of sales that had already been made to these distributors. Excluding these costs, Merck's consumer segment would have posted sales growth of 1% (including the negative currency effect), which is still below that of J&J.

There is also a significant amount of crossover between J&J's consumer segment and Procter & Gamble (NYSE:PG), which is solely focused on consumer goods. It posted total sales growth of 1% in 2013, although as with J&J and Merck, there was a negative impact from foreign exchange, which reduced net sales growth by 2%. Were it not for this, Procter & Gamble would have recorded the highest sales growth of the three companies, being slightly ahead of J&J's 2.8% growth and well ahead of Merck's sales decline of 2% (figures exclude the negative impact of foreign exchange fluctuations).

The reason for Procter & Gamble's strong relative top-line increase was a mix of price and volume growth, with baby care and family care franchises showing strong volume growth in particular and health care also making improvements on the prior year.

Looking ahead
Although top-line growth at J&J was slightly below that of Procter & Gamble, 2.8% (excluding currency impact) is still relatively strong. Certainly, Merck's 2% decline (excluding currency impact) was significantly affected by one-off items, but it still shows that J&J's consumer segment is holding its own among peers.

Indeed, the consumer segment is an important part of J&J and, I feel, is often overlooked by some investors. That's because it doesn't provide the highs of the pharma segment, in terms of creating blockbuster drugs that can make a huge difference to an already vast top line. In other words, it isn't as exciting as the pharma segment. However, while it doesn't come with the highs, it also doesn't deliver the lows of patent expiry and instead provides stability, modest growth, and a reliable, repeat income for J&J.

As such, while the consumer segment may not be prove to be a super-hot catalyst for J&J in 2014, it plays a key role in diversifying the company's operations and in generating top- and bottom-line growth for the business. In the long run, this should be valued by investors and, I believe, will mean a strong showing from J&J's share price over the long run, too.

Boost your 2014 returns with The Motley Fool's top stock
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens has no position in any stocks mentioned. The Motley Fool recommends Procter & Gamble. It recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 10:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers